|1.||Rosenstock, Julio: 16 articles (09/2014 - 11/2003)|
|2.||Gerstein, Hertzel C: 12 articles (10/2014 - 11/2007)|
|3.||Riddle, Matthew C: 11 articles (12/2014 - 11/2003)|
|4.||Wei, Wenhui: 9 articles (05/2014 - 01/2011)|
|5.||Dailey, George: 8 articles (12/2014 - 04/2005)|
|6.||Baser, Onur: 8 articles (09/2014 - 01/2011)|
|7.||Xie, Lin: 7 articles (09/2014 - 01/2011)|
|8.||Garg, Satish K: 7 articles (02/2014 - 02/2004)|
|9.||Buse, John B: 6 articles (01/2016 - 01/2011)|
|10.||Home, P D: 6 articles (09/2015 - 04/2007)|
|1.||Hypoglycemia (Reactive Hypoglycemia)
01/01/2011 - "the AT-LANTUS Study demonstrated that a simple subject-administered titration algorithm significantly improved glycemic control with a low incidence of severe hypoglycemia compared with a physician-managed titration. "
05/01/2014 - "Reductions in HbA1c level and hypoglycemia rates were significantly greater with glargine use than with intensification of OADs or lifestyle modifications, overall, and in patients with any CVRF. "
06/01/2013 - "Insulin glargine was associated with better glycemic control and a reduced incidence of daytime and any hypoglycemia versus comparator interventions in both younger and older T2DM patients. "
05/01/2005 - "The use of FMDI therapy with glargine among preschool-aged children with type 1 DM was associated with improved overall glycemic control and decreased frequency of severe hypoglycemia. "
12/01/2013 - "Based on reduced incidence of hypoglycemia and possibility for flexibility around timing of dose administration, use of degludec is likely to be cost-effective compared to glargine from a societal perspective in T1D, T2-BOT, and T2-BB in Sweden over a 1-year time horizon."
|2.||Type 2 Diabetes Mellitus (MODY)
01/01/2015 - "An Open-label Longitudinal Study on the Efficacy of Switching from Insulin Glargine or Detemir to Degludec in Type 2 Diabetes Mellitus."
01/01/2015 - "We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR® or ClikSTAR® pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland. "
05/01/2013 - "The objective of the current study was to evaluate real-world clinical and economic outcomes of patients with type 2 diabetes mellitus (T2DM) initiating insulin glargine via pen delivery (pen) or vial/syringe (vial) within a large managed-care population in the United States. "
03/01/2013 - "The study was designed to evaluate real-world data on clinical and economic outcome differences between patients with type 2 diabetes mellitus (T2DM) who use insulin glargine with vial-and-syringe delivery and those who switch to pen administration. "
03/01/2013 - "A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus."
08/01/2010 - "In this study, treatment with insulin glargine in people with T2DM was associated with a significant reduction in HbA1c without differential increase in weight gain in obese and non-obese subgroups. "
01/01/2005 - "Better A1c reductions were obtained with premeal GLU, but postmeal administration of GLU was as safe and effective as premeal GLU or RHI in combination with insulin glargine and was not associated with weight gain."
01/01/2006 - "Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain."
08/01/2011 - "However, most insulin glargine studies have reported a weight gain. "
10/01/2004 - "The weight gain was significantly higher in the NPH group at the end of the study (P = 0.004) with no significant change in the glargine group. "
12/01/2012 - "Regular SC administration of insulin glargine was successful in the treatment of diabetes mellitus in the ferret of this report and may be effective for other diabetic ferrets."
01/01/2012 - "The objective of this study was to evaluate the safety and efficacy of insulin glargine in dogs with diabetes mellitus (DM). "
03/01/2014 - "This paper discusses the most recent studies in patients with type 1 and 2 diabetes mellitus, which showed degludec to be non inferior in decreasing HbA1c, ensuring optimum glycemic control similar to that achieved with insulin glargine or detemir. "
03/01/2009 - "There are only a limited number of high quality studies showing that insulin glargine is superior regarding treatment satisfaction and HRQoL of patients with diabetes mellitus. "
09/01/2014 - " words: basal-bolus regimen - diabetes mellitus - insulin glargine - observational project."
11/01/2007 - "Perceived frequency of hyperglycemia improved with glargine at week 12, and no difference was found at 24 weeks. "
09/01/2014 - "The currently proposed weight-based insulin glargine dose titration regimen is effective, tolerable, and user-friendly at achieving FBG target levels in hospitalized patients with hyperglycemia."
04/01/2014 - "With respect to hyperglycemia type, there was no difference between NPH and glargine in their effects on HbA1c. "
12/01/2012 - "An insulin glargine adjustment strategy based on usual glycemic control may better prevent severe preoperative hyperglycemia in patients receiving basal/bolus regimens."
07/01/2012 - "Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine."
|3.||glargine (insulin glargine)
|5.||Blood Glucose (Blood Sugar)
|9.||insulin detemir (Levemir)
|10.||insulin aspart (NovoLog)
|2.||Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
|4.||Transplantation (Transplant Recipients)